Cesca Therapeutics Inc. (Nasdaq: KOOL), a market leader in automated cell processing and autologous cell therapies for regenerative medicine, today announced that on June 25, 2019 the Company received notification from the Qualifications Department of The Nasdaq Stock Market (“Nasdaq”) that it has regained compliance with Nasdaq Listing Rule 5550(a)(2)
RANCHO CORDOVA, Calif., June 26, 2019 /PRNewswire/ -- Cesca Therapeutics Inc. (Nasdaq: KOOL), a market leader in automated cell processing and autologous cell therapies for regenerative medicine, today announced that on June 25, 2019 the Company received notification from the Qualifications Department of The Nasdaq Stock Market (“Nasdaq”) that it has regained compliance with Nasdaq Listing Rule 5550(a)(2), which concerns minimum bid price listing requirements. The Company’s shares will continue to be traded on The Nasdaq Stock Market under the Symbol KOOL. “We are pleased to be in full compliance with these continued listing standards,” said Chris Xu, Cesca’s Chief Executive Officer. “We can now put this behind us and work hard to ensure that our share price continues to appreciate in response to our ongoing business growth and success.” About Cesca Therapeutics Inc. Forward-Looking Statement Company Contact: Investor Contact:
SOURCE Cesca Therapeutics Inc. | ||
Company Codes: NASDAQ-SMALL:KOOL |